Trial reportInternational journal of radiation oncology, biology, physics2026
Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.
Trial report in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
purposeLocal therapy (LT) is a critical component of curative treatment for Ewing sarcoma (ES). This analysis evaluated clinical and treatment variables associated with local failure (LF) risk for nonmetastatic patients with ES. METHODS AND MATERIALS: AEWS1031 was a phase 3 randomized trial comparing 2 interval-compressed chemotherapy regimens. Patients who completed induction chemotherapy and started LT of the primary tumor site were analyzed. LT was surgery alone (S), definitive radiation therapy (RT), or surgery and RT (S+RT), and was determined by the treating investigator. The primary endpoint was the cumulative incidence of LF estimated from the time LT was started. Elastic net penalization was used to identify predictors associated with the cause-specific hazard rates of LF.
resultsFive hundred eighty-eight patients started LT. Tumor sites were extremity (40%), axial (27%), pelvis (18%), and extraosseous (15%). LT was S (54%), RT (27%), and S+RT (18%). With a median follow-up of 67.6 months, the 5-year cumulative incidence of LF for all patients was 6%. LF incidence was 5% for S, 8.4% for RT, and 5.6% for S+RT (P = .47). LF incidence was 3.5% for extremity, 8.7% for pelvis, 7.7% for axial, and 6.3% for extraosseous (P = .09). LF incidence was higher for tumors ≥200 mL (11.3%) compared with tumors <200 mL (3.9%; P < .01). On multivariable modeling, increasing age at enrollment (cause-specific relative hazard ratio [csRHR] 1.04/y) and increasing maximum tumor dimension (csRHR 1.08/cm) were suggestive of a higher incidence of LF. By tumor subsite, axial tumors were associated with the highest risk of LF (csRHR 1.17) and extremity tumors with the lowest risk (csRHR 0.50).
conclusionsWe report the lowest LF incidence to date for prospective ES trials. Large tumors, older age, and axial tumor subsite were associated with higher LF incidence, indicating further efforts are needed to identify the highest-risk subset most likely to benefit from improved LT strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.